Aptorum Group has regained compliance with Nasdaq's bid price requirement and announced a merger with DiamiR Biosciences.
Quiver AI Summary
Aptorum Group Limited announced that it has regained compliance with Nasdaq's minimum bid price requirement after its Class A ordinary shares maintained a closing bid price of at least $1.00 for ten consecutive business days, a condition that was met from July 16 to July 30, 2025. This compliance resolves the matter originally raised by Nasdaq on April 15, 2025. Additionally, Aptorum revealed it has entered into a definitive agreement for an all-stock merger with DiamiR Biosciences, a company specializing in innovative blood-based tests for brain health, which will make DiamiR a wholly-owned subsidiary of Aptorum upon completion of the merger. Aptorum Group focuses on developing therapeutic assets to address unmet medical needs, particularly in oncology and infectious diseases.
Potential Positives
- Aptorum Group has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the exchange.
- The company successfully maintained a closing bid price of at least $1.00 per share for 10 consecutive business days, demonstrating stability in its stock performance.
- Aptorum announced a significant all-stock merger agreement with DiamiR Biosciences, expanding its portfolio in the diagnostics sector with innovative blood-based tests.
- The merger with DiamiR Biosciences will enhance Aptorum's capabilities in the clinical diagnostics market, potentially leading to new growth opportunities and addressing unmet medical needs.
Potential Negatives
- The press release indicates the company had previously been at risk of being delisted from Nasdaq, suggesting ongoing issues with its stock performance.
- Regaining compliance only highlights the temporary resolution of a pressing financial issue rather than a significant turnaround in the company's overall market standing.
- The focus on an all-stock merger may imply a reliance on equity financing over more stable forms of capital, which could raise concerns about future dilution of existing shareholders' value.
FAQ
What recent compliance milestone did Aptorum Group achieve with Nasdaq?
Aptorum Group has regained compliance with Nasdaq’s minimum bid price requirement, closing above $1.00 for ten consecutive business days.
What was the closing bid price period for Aptorum Group?
The closing bid price of Aptorum's shares was at least $1.00 from July 16, 2025, to July 30, 2025.
What merger announcement did Aptorum Group make recently?
Aptorum announced a definitive agreement for an all-stock merger with DiamiR Biosciences, focusing on blood-based tests for brain health.
What is DiamiR Biosciences known for?
DiamiR is known for developing minimally invasive tests for early detection and monitoring of brain health conditions and diseases.
Where can I find more information about Aptorum Group?
More information about Aptorum Group can be found on their website at www.aptorumgroup.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$APM Hedge Fund Activity
We have seen 5 institutional investors add shares of $APM stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 17,208 shares (+inf%) to their portfolio in Q1 2025, for an estimated $14,454
- MORGAN STANLEY added 12,138 shares (+134.6%) to their portfolio in Q1 2025, for an estimated $10,195
- XTX TOPCO LTD added 10,039 shares (+inf%) to their portfolio in Q1 2025, for an estimated $8,432
- UBS GROUP AG added 3,139 shares (+1480.7%) to their portfolio in Q1 2025, for an estimated $2,636
- GEODE CAPITAL MANAGEMENT, LLC removed 1,442 shares (-3.8%) from their portfolio in Q1 2025, for an estimated $1,211
- SBI SECURITIES CO., LTD. removed 68 shares (-50.4%) from their portfolio in Q1 2025, for an estimated $57
- CITIGROUP INC added 19 shares (+inf%) to their portfolio in Q1 2025, for an estimated $15
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq’s minimum bid price requirement.
The regaining of compliance is a result of the closing bid price of the company’s Class A ordinary shares being at least $1.00 for a minimum of 10 consecutive business days prior to the October 14, 2025 deadline, as described in the initial notice from Nasdaq to the company dated April 15, 2025.
The closing bid price has been $1.00 per share or greater for the 10 consecutive business days from July 16, 2025 to July 30, 2025. Accordingly, the Nasdaq Listing Qualification Staff has notified the company that it has determined that the company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.
On July 14, 2025 Aptorum announced that it entered into a definitive agreement for an all-stock merger transaction with DiamiR Biosciences, a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA-licensed, CAP-accredited clinical laboratory in New Haven, CT. As a result of this transaction and subject to the customary closing conditions, DiamiR Biosciences will become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company’s website at www.aptorumgroup.com .
About DiamiR Biosciences
DiamiR is a private molecular diagnostics company focused on developing and commercializing minimally invasive tests offered through its CLIA/CAP-certified laboratory for early detection and monitoring of brain health conditions and other diseases in clinical trials and clinical practice settings. DiamiR’s proprietary platform technology, protected by over 50 issued patents worldwide, is based on quantitative analysis of organ-enriched, including brain-enriched and inflammation-associated, microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. In addition, DiamiR offers protein and genetic biomarker analyses. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies. For more information, please visit the company's website at www.diamirbio.com and connect with DiamiR on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.
For more information, please contact:
Aptorum Group Limited
Investor Relations Department
[email protected]
+44 20 80929299
